We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AACC Middle East to Showcase Latest in Laboratory Medicine and Diagnostic Innovations

By LabMedica International staff writers
Posted on 25 Oct 2022
Print article
Image: AACC and Life Dx are bringing the latest developments in laboratory medicine to the Middle East region (Photo courtesy of AACC)
Image: AACC and Life Dx are bringing the latest developments in laboratory medicine to the Middle East region (Photo courtesy of AACC)

AACC Middle East, a two-day conference held by the American Association for Clinical Chemistry (Washington, DC, USA) in partnership with Life Dx (Abu Dhabi, UAE) will bring the latest in laboratory medicine to the Middle East region and showcase diagnostic innovations. The conference will cover a range of timely topics from infectious disease to big data to prenatal emerging technology as well as core laboratory areas in sample transport, lab management, and quality assurance. Each session will be presented by experts in AACC's scientific leadership to bring the latest in laboratory medicine and build new networks among attendees.

The conference to be held in the Grand Hyatt in Dubai, UAE, from November 5-6 will deliver the latest scientific advances in all disciplines pertinent to the field of laboratory medicine. Leaders in laboratory science and management from countries throughout the region including United Arab Emirates, Kuwait, Oman, Bahrain, Qatar, Saudi Arabia, Jordan, Egypt, Turkey, Lebanon, Cyprus, and the entire African continent have been invited to participate. Attendees will include laboratory directors and managers, government officials, and representatives of the diagnostics industry. AACC Middle East attendees will also have the opportunity to network with their peers and experts from the U.S. and the Middle East to share knowledge on new breakthroughs in laboratory medicine. The conference is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), medical technologists, pathologists, immunologists, fellows, residents, in-training individuals, and other healthcare professionals interested in laboratory medicine.

AACC Middle East attendees will be able to discuss state-of-the-art research and technologies in laboratory medicine, and incorporate laboratory management strategies that enhance workflows and support accurate and effective testing to improve treatment decisions and patient outcomes. They will also be able to implement up-to-date laboratory testing methods, technologies, and data-driven approaches in the preanalytical, analytical, and postanalytical phases of sample handling. Additionally, participants will be able to describe applications and considerations of data analytics and machine learning in clinical laboratories, summarize advances in biomarkers and screening for neurological disease, assessment of kidney function, preeclampsia, and newborn screening, and demonstrate the value and role of laboratory medicine in treatment decisions and patient outcomes.

Related Links:
AACC
Life Dx

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Sekisui Diagnostics UK Ltd.